This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

ASCO '12: Roche, ImmunoGen Drug Delays Breast Tumor Growth

CHICAGO ( TheStreet) -- An experimental antibody-drug conjugate therapy from the Genentech unit of Roche (RHHBY) delayed by more than three months the re-growth of breast cancer compared to the current standard of care, according to a phase III study being presented today at the American Society of Clinical Oncology (ASCO) annual meeting.

The drug, known as T-DM1, will be filed for regulatory approval in the U.S. and Europe later this year, Roche said.

T-DM1 is a second-generation version of Genentech's blockbuster breast cancer drug Herceptin. The drug consists of Herceptin (also known as trastuzumab) linked to a tumor-killing chemotherapy payload developed by ImmunoGen (IMGN - Get Report).

The phase III enrolled 1,000 women with advanced, metastatic Her-2 positive breast cancer who were ready for second-line therapy, having been previously treated with Herceptin and chemotherapy. The women were randomized to treatment with either TDM-1 or a combination of Roche's Xeloda and GlaxoSmithKline's (GSK - Get Report) Tykerb, which is approved for second-line breast cancer treatment.

Breast cancer patients treated with TDM-1 lived a median of 9.6 months before their cancer progressed compared to 6.4 months for the patients treated with the Xeloda-Tykerb combination. The benefit, which equates to a 35% reduction in the risk of disease progression favoring TDM-1, was statistically significant.

After two years of follow-up, 65.4% of TDM-1 patients were alive compared to 47.5% of patients treated with Xeloda-Tykerb. This improvement in survival is not yet statistically significant but Genentech continues to follow these patients and additional survival analyses will be conducted, the company said.

TDM-1 caused more patients to suffer from reduced platelet counts but the Xeloda-Tykerb combination caused more diarrhea, hand-foot syndrome and vomiting. Sixteen percent of patients had to reduce the dose of TDM-1 during treatment compared to 53% of patients treated with Xeloda-Tykerb.

"The drug TDM-1 worked. It was significantly better than a very effective approved therapy for HER2 overexpressing metastatic breast cancer," said Dr. Kimberly Blackwell, professor of medicine at Duke University's Cancer Institute. "Also, as a clinician who takes care of a lot of breast cancer patients, I’m pleased that this drug has very little dose-limiting toxicity. Patients don't lose their hair from this drug. For patients facing metastatic breast cancer, this is a breakthrough."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
RHHBY $34.12 0.38%
GSK $47.59 -0.71%
IMGN $7.47 -5.30%
AAPL $128.41 -0.53%
FB $78.69 -1.30%

Markets

DOW 18,144.55 -144.08 -0.79%
S&P 500 2,103.95 -13.44 -0.63%
NASDAQ 4,968.6740 -39.4220 -0.79%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs